Cyclophosphamide in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

The article reports a systematic review and meta-analysis on the use of cyclophosphamide in patients with systemic sclerosis-associated interstitial lung disease. Key topics include risk of bias in randomized controlled trials, summary of evidence for cyclophosphamide versus placebo, and important outcomes such as adverse events and changes in pulmonary function.